We have established a strategic drug discovery and development alliance with MD Anderson Cancer Center's Oncology Research for Biologics and Immunotherapy Translation (ORBIT) group to discover and develop novel human therapeutic antibodies to treat a variety of cancers.
Our collaboration combines our industry-leading antibody platform and our in-house discovery and development experience together with MD Anderson’s novel target biology, clinical datasets, translational and clinical infrastructure to develop products to clinical proof of concept.
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centres focused on cancer patient care, research, education and prevention.
The University of Texas MD Anderson Cancer Center's sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 45 comprehensive cancer centres designated by the National Cancer Institute (NCI). ORBIT (Oncology Research for Biologics and Immunotherapy Translation) platform is a novel centralised organisation within MD Anderson with the mission of making MD Anderson a recognised leader in the discovery and development of novel monoclonal antibodies.
The ORBIT team focuses on combining scientific excellence with industry standard and is committed to accelerate and execute the translation of novel discoveries into clinically relevant anti-cancer monoclonal antibodies.